-
公开(公告)号：WO2022103773A1
公开(公告)日：2022-05-19
申请号：PCT/US2021/058669
申请日：2021-11-09
Applicant: AMGEN INC.
Inventor： RILEY, Timothy , GARCES, Fernando , WANG, Zhulun , ESTES, Bram , BATES, Darren L.
IPC: C07K16/00
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.
-
公开(公告)号：WO2022256563A1
公开(公告)日：2022-12-08
申请号：PCT/US2022/032011
申请日：2022-06-02
Applicant: AMGEN INC. , AMGEN RESEARCH (MUNICH) GMBH
Inventor： PIERCE, Nathan William , KIELCZEWSKA, Agnieszka , CHEN, Wentao , NOLAN-STEVAUX, Olivier , BATES, Darren L. , WINKEL, Lisa , DAHLHOFF, Christoph , RAUM, Tobias , BLUEMEL, Claudia , HONER, Jonas Karl-Josef
IPC: C07K16/28 , A61K39/00 , A61K2039/507 , C07K16/2818 , C07K16/2866 , C07K2317/34 , C07K2317/41 , C07K2317/569 , C07K2317/73 , C07K2317/732 , C07K2317/92
Abstract: The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.
-
Patent Agency Ranking
公开(公告)号：WO2021030602A1
公开(公告)日：2021-02-18
申请号：PCT/US2020/046202
申请日：2020-08-13
Applicant: AMGEN INC.
Inventor： BATES, Darren L. , SOHN, Sue J. , CATTERALL, Hannah , WANG, Zhulun
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
-
4.发明申请METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS 审中-公开使用结合蛋白治疗或改善代谢性疾病的方法用于胃泌受体肽受体（GIPR）与GLP-1激动剂组合
公开(公告)号：WO2017112824A2
公开(公告)日：2017-06-29
申请号：PCT/US2016/068138
申请日：2016-12-21
Applicant: AMGEN INC.
Inventor： YIE, Junming , SHI, Donghui , LLOYD, David J. , WANG, Jinghong , SIVITS, JR., Glenn N. , VENIANT-ELLISON, Murielle M. , KOMOROWSKI, Renee , AGRAWAL, Neeraj , BATES, Darren L. , CLAVETTE, Brandon C. P. , FOLTZ, Ian N. , HO, Shu-yin , MURAWSKY, Christopher , MIN, Xiaoshan , WANG, Zhulun
IPC: C07K16/28
CPC classification number: C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
Abstract translation: 提供了使用对GIPR多肽特异的抗原结合蛋白治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰岛素水平升高和糖尿病性肾病。 在某些实施方案中，抗原结合蛋白与GLP-1受体激动剂联合给药。
-
5.发明申请
公开(公告)号：WO2022261299A1
公开(公告)日：2022-12-15
申请号：PCT/US2022/032801
申请日：2022-06-09
Applicant: AMGEN INC.
Inventor： BATES, Darren L. , LIU, Zhi , LEE, TaeWeon , MICHAELS, Mark L. , WANG, Zhulun
IPC: A61P9/10 , C07K14/475
Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.
-
公开(公告)号：WO2018237097A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038638
申请日：2018-06-20
Applicant: AMGEN INC.
Inventor： BATES, Darren L. , SHI, Donghui , LLOYD, David J. , BONDARENKO, Pavel , MICHAELS, Mark L. , HAGER, Todd , MIN, Xiaoshan , UMEDA, Aiko , CHEN, Irwin , WANG, Zhulun
IPC: C07K16/28
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：WO2017112824A8
公开(公告)日：2017-06-29
申请号：PCT/US2016/068138
申请日：2016-12-21
Applicant: AMGEN INC.
Inventor： YIE, Junming , SHI, Donghui , LLOYD, David J. , WANG, Jinghong , SIVITS, JR., Glenn N. , VENIANT-ELLISON, Murielle M. , KOMOROWSKI, Renee , AGRAWAL, Neeraj , BATES, Darren L. , CLAVETTE, Brandon C. P. , FOLTZ, Ian N. , HO, Shu-yin , MURAWSKY, Christopher , MIN, Xiaoshan , WANG, Zhulun
IPC: C07K16/28 , A61K38/26 , A61K39/395 , A61P3/10
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
-
-
-
-
-
Search Results
7
records
(took 0.015 seconds)
